Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 18/20 | 0.93 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL3388 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL204535 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5984073 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL536412 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3110183 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973704 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14840776 | 0.96 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL2282827 | 0.96 | FDPS (0.93) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL328770 | 0.96 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL7749180 | 0.94 | FDPS (0.89) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030926-B2 | Production of heteromultimeric proteins using mammalian cells | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240200146-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240190967-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240175088-A1 | Methods and Systems for Analyzing Nucleic Acid Molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240158513-A1 | FC Variants and Methods for Their Production | GENENTECH, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC | 2024-05-09 | — | — | US | disclosed |
| US-11965215-B2 | Methods and systems for analyzing nucleic acid molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4334476-A1 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | GENENTECH, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2006026759-A2 | HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR | GENENTECH, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006015371-A2 | HUMANIZED ANTI-CMET ANTAGONISTS | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014335-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKIN’S LYMPHOMA | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272120-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050170368-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050106667-A1 | Variant complementary determining regions for use in identifying antigen binding polypeptides; mimetics; direceted protein evolution | GENENTECH, INC | 2005-05-19 | — | — | US | disclosed |
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | GENENTECH, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005012531-A2 | ANTIBODY CDR POLYPEPTIDE SEQUENCES WITH RESTRICTED DIVERSITY | GENENTECH, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005002582-A2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003154-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067709-A1 | Methods and Compositions for Targeting Polyubiquitin | PSMG3, STUB1, USP47 | FDPS 4682/4885PDE3A 4792/4885LMNA 1356/4885 |
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | TSG101, TP53, BAX | FDPS 1871/4885PDE3A 1861/4885LMNA 1599/4885 |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | CNR2, CNR1, FAAH | FDPS 1169/4885PDE3A 2026/4885LMNA 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.